Ligand ID: H8G


Drugbank ID:
DB00589
(Lisuride)


Indication:
For the management of Parkinson's Disease

Get human targets for H8G in PDB (known and potential targets)

RESULTS FROM SUB-STRUCTURAL SIMILARITY SEARCHES MAPPED TO LIGAND 'H8G'

Click here for results that match SARS-Cov-2 / COVID-19 structures only
Click here for results that match SARS-related structures only


1) User may click on the DrReposER ID (the second column) to get information on the binding sites and drug molecule.
2) Click View (the second last column) to view matched residues and superposition in the NGL viewer (upper right part).
3) User may also click on the Dock (the last column) to get script for molecular docking in UCSF Chimera through AutoDock Vina.

DrReposER ID / Desc. Hit
PDBID		 Hit
Macromolecule		 Res.
Matches		 View Interface RMSD Seq.
Identity (%)		 HETATM Dock
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DRX_A_H8GA1201_0
(5HT2B RECEPTOR, BRIL
CHIMERA)		2dd8 SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
VAL S 420
THR S 363
PHE S 387
ALA S 422
PHE S 329
1.51A18.85
None
None
None
None
NAG  S1330 (-4.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DRX_A_H8GA1201_0
(5HT2B RECEPTOR, BRIL
CHIMERA)		2ghw SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
VAL C 420
THR C 363
ALA C 422
PHE C 329
TYR C 352
1.61A18.32
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DRX_A_H8GA1201_0
(5HT2B RECEPTOR, BRIL
CHIMERA)		2rhb URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARSr-CoV)		5 / 12
VAL F 275
SER F 273
THR F 274
ALA F 325
VAL D  35
1.36A22.48
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DRX_A_H8GA1201_0
(5HT2B RECEPTOR, BRIL
CHIMERA)		3d0g ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		5 / 12
LEU A 570
VAL A 573
ALA A 550
VAL A 404
TYR A 381
1.53A20.13
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DRX_A_H8GA1201_0
(5HT2B RECEPTOR, BRIL
CHIMERA)		3d0g SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
VAL F 382
PHE F 501
ALA F 350
PHE F 329
VAL F 328
1.61A17.47
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DRX_A_H8GA1201_0
(5HT2B RECEPTOR, BRIL
CHIMERA)		3scj ACE2
(Homo
sapiens)		5 / 12
LEU A 570
VAL A 573
ALA A 550
VAL A 404
TYR A 381
1.50A20.26
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DRX_A_H8GA1201_0
(5HT2B RECEPTOR, BRIL
CHIMERA)		5wrg SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
VAL B 382
PHE B 501
ALA B 350
PHE B 329
VAL B 328
1.62A17.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DRX_A_H8GA1201_0
(5HT2B RECEPTOR, BRIL
CHIMERA)		5x5b SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		5 / 12
VAL C 711
SER C1003
PHE C 764
ALA C1008
VAL C 708
1.38A17.70
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DRX_A_H8GA1201_0
(5HT2B RECEPTOR, BRIL
CHIMERA)		5x5c S PROTEIN
(MERS-CoV)		5 / 12
LEU C 952
ALA C 973
PHE C1001
ASN C1002
VAL C1139
1.62A14.07
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DRX_A_H8GA1201_0
(5HT2B RECEPTOR, BRIL
CHIMERA)		6acc SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
VAL B 382
PHE B 501
ALA B 350
PHE B 329
VAL B 328
1.46A17.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DRX_A_H8GA1201_0
(5HT2B RECEPTOR, BRIL
CHIMERA)		6crv SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 12
VAL C 711
SER C1003
PHE C 764
ALA C1008
PHE C1044
1.51A17.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DRX_A_H8GA1201_0
(5HT2B RECEPTOR, BRIL
CHIMERA)		6cs1 SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 12
VAL C 711
SER C1003
PHE C 764
ALA C1008
PHE C1044
1.39A17.91
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DRX_A_H8GA1201_0
(5HT2B RECEPTOR, BRIL
CHIMERA)		6lze VIRAL PROTEASE
(SARS-CoV-2)		5 / 12
LEU A  89
VAL A  91
THR A  93
ALA A  94
VAL A  18
1.74A21.88
None
None
None
None
DMS  A 403 ( 4.9A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DRX_A_H8GA1201_0
(5HT2B RECEPTOR, BRIL
CHIMERA)		6lzg SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
VAL B 395
PHE B 515
ALA B 363
PHE B 342
VAL B 341
1.54A18.96
None
None
None
NAG  B 601 (-4.5A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DRX_A_H8GA1201_0
(5HT2B RECEPTOR, BRIL
CHIMERA)		6lzg ACE2
(Homo
sapiens)		5 / 12
LEU A 570
VAL A 573
ALA A 550
VAL A 404
TYR A 381
1.52A20.33
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DRX_A_H8GA1201_0
(5HT2B RECEPTOR, BRIL
CHIMERA)		6m18 SODIUM-DEPENDENT
NEUTRAL AMINO ACID
TRANSPORTER B(0)AT1
(Homo
sapiens)		5 / 12
LEU A 286
SER A 122
THR A 121
ALA A 117
VAL A 441
1.44A20.42
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DRX_A_H8GA1201_0
(5HT2B RECEPTOR, BRIL
CHIMERA)		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 12
LEU B  89
VAL B  91
THR B  93
ALA B  94
VAL B  18
1.75A21.67
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DRX_A_H8GA1201_0
(5HT2B RECEPTOR, BRIL
CHIMERA)		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 12
LEU D  89
VAL D  91
THR D  93
ALA D  94
VAL D  18
1.73A21.67
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DRX_A_H8GA1201_0
(5HT2B RECEPTOR, BRIL
CHIMERA)		6m71 NSP12
(SARS-CoV-2)		5 / 12
LEU A 630
THR A 687
ALA A 688
PHE A 480
VAL A 637
1.66A19.02
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DRX_A_H8GA1201_0
(5HT2B RECEPTOR, BRIL
CHIMERA)		6m71 NSP12
(SARS-CoV-2)		5 / 12
LEU A 786
SER A 778
ALA A 706
PHE A 753
VAL A 764
1.61A19.02
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DRX_A_H8GA1201_0
(5HT2B RECEPTOR, BRIL
CHIMERA)		6m71 NSP12
(SARS-CoV-2)		5 / 12
VAL A 476
ALA A 634
ASN A 695
VAL A 587
TYR A 483
1.67A19.02
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DRX_A_H8GA1201_0
(5HT2B RECEPTOR, BRIL
CHIMERA)		6m71 NSP12
(SARS-CoV-2)		5 / 12
LEU A 731
SER A 709
THR A 710
ASN A 703
VAL A 785
1.72A19.02
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DRX_A_H8GA1201_0
(5HT2B RECEPTOR, BRIL
CHIMERA)		6nb6 SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
VAL C 711
SER C1003
PHE C 764
ALA C1008
VAL C 708
1.41A17.11
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DRX_A_H8GA1201_0
(5HT2B RECEPTOR, BRIL
CHIMERA)		6nus NSP12
(SARSr-CoV)		5 / 12
LEU A 786
SER A 778
ALA A 706
PHE A 753
VAL A 764
1.53A18.32
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DRX_A_H8GA1201_0
(5HT2B RECEPTOR, BRIL
CHIMERA)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
VAL C 395
PHE C 515
ALA C 363
PHE C 342
VAL C 341
1.60A16.92
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DRX_A_H8GA1201_0
(5HT2B RECEPTOR, BRIL
CHIMERA)		6vw1 SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
VAL F 395
PHE F 515
ALA F 363
PHE F 342
VAL F 341
1.53A17.51
None
None
None
NAG  F 601 (-4.8A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DRX_A_H8GA1201_0
(5HT2B RECEPTOR, BRIL
CHIMERA)		6vxs NSP3
(SARS-CoV-2)		5 / 12
LEU B  93
VAL B  35
ALA B  27
ASN B   4
VAL B 151
1.64A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DRX_A_H8GA1201_0
(5HT2B RECEPTOR, BRIL
CHIMERA)		6vxs NSP3
(SARS-CoV-2)		5 / 12
LEU A  93
VAL A  35
ALA A  27
PHE A   6
ASN A   4
1.50A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DRX_A_H8GA1201_0
(5HT2B RECEPTOR, BRIL
CHIMERA)		6vxs NSP3
(SARS-CoV-2)		5 / 12
LEU B  93
VAL B  35
ALA B  27
PHE B   6
ASN B   4
1.53A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DRX_A_H8GA1201_0
(5HT2B RECEPTOR, BRIL
CHIMERA)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
VAL B 729
SER B1021
PHE B 782
ALA B1026
PHE B1062
1.52A16.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DRX_A_H8GA1201_0
(5HT2B RECEPTOR, BRIL
CHIMERA)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
VAL A 395
PHE A 515
ALA A 363
PHE A 342
VAL A 341
1.49A16.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DRX_A_H8GA1201_0
(5HT2B RECEPTOR, BRIL
CHIMERA)		6w02 NSP3
(SARS-CoV-2)		5 / 12
LEU A  93
VAL A  35
ALA A  27
PHE A   6
ASN A   4
1.50A16.46
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DRX_A_H8GA1201_0
(5HT2B RECEPTOR, BRIL
CHIMERA)		6w6y NSP3
(SARS-CoV-2)		5 / 12
LEU B  93
VAL B  35
ALA B  27
PHE B   6
ASN B   4
1.48A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DRX_A_H8GA1201_0
(5HT2B RECEPTOR, BRIL
CHIMERA)		6w6y NSP3
(SARS-CoV-2)		5 / 12
LEU A  93
VAL A  35
ALA A  27
PHE A   6
ASN A   4
1.47A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DRX_A_H8GA1201_0
(5HT2B RECEPTOR, BRIL
CHIMERA)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		5 / 12
SER B 170
THR B 168
PHE B 127
PHE B 241
VAL B 205
1.58A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DRX_A_H8GA1201_0
(5HT2B RECEPTOR, BRIL
CHIMERA)		6wcf NSP3
(SARS-CoV-2)		5 / 12
LEU A  93
VAL A  35
ALA A  27
ASN A   4
VAL A 151
1.62A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DRX_A_H8GA1201_0
(5HT2B RECEPTOR, BRIL
CHIMERA)		6wcf NSP3
(SARS-CoV-2)		5 / 12
LEU A  93
VAL A  35
ALA A  27
PHE A   6
ASN A   4
1.54A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DRX_A_H8GA1201_0
(5HT2B RECEPTOR, BRIL
CHIMERA)		6wen NSP3
(SARS-CoV-2)		5 / 12
LEU A  93
VAL A  35
ALA A  27
PHE A   6
ASN A   4
1.43A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DRX_A_H8GA1201_0
(5HT2B RECEPTOR, BRIL
CHIMERA)		6wey NSP3
(SARS-CoV-2)		5 / 12
LEU A 297
VAL A 239
ALA A 231
ASN A 208
VAL A 355
1.60A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DRX_A_H8GA1201_0
(5HT2B RECEPTOR, BRIL
CHIMERA)		6wey NSP3
(SARS-CoV-2)		5 / 12
LEU A 297
VAL A 239
ALA A 231
PHE A 210
ASN A 208
1.44A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DRX_A_H8GA1201_0
(5HT2B RECEPTOR, BRIL
CHIMERA)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
LEU A  93
VAL A  35
ALA A  27
ASN A   4
VAL A 151
1.61A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DRX_A_H8GA1201_0
(5HT2B RECEPTOR, BRIL
CHIMERA)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
LEU D  93
VAL D  35
ALA D  27
ASN D   4
VAL D 151
1.57A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DRX_A_H8GA1201_0
(5HT2B RECEPTOR, BRIL
CHIMERA)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
LEU C  93
VAL C  35
ALA C  27
PHE C   6
ASN C   4
1.45A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DRX_A_H8GA1201_0
(5HT2B RECEPTOR, BRIL
CHIMERA)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
LEU B  93
VAL B  35
ALA B  27
PHE B   6
ASN B   4
1.47A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DRX_A_H8GA1201_0
(5HT2B RECEPTOR, BRIL
CHIMERA)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
LEU C  93
VAL C  35
ALA C  27
ASN C   4
VAL C 151
1.57A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DRX_A_H8GA1201_0
(5HT2B RECEPTOR, BRIL
CHIMERA)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
LEU A  93
VAL A  35
ALA A  27
PHE A   6
ASN A   4
1.45A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DRX_A_H8GA1201_0
(5HT2B RECEPTOR, BRIL
CHIMERA)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
LEU B  93
VAL B  35
ALA B  27
ASN B   4
VAL B 151
1.59A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DRX_A_H8GA1201_0
(5HT2B RECEPTOR, BRIL
CHIMERA)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
LEU D  93
VAL D  35
ALA D  27
PHE D   6
ASN D   4
1.43A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DRX_A_H8GA1201_0
(5HT2B RECEPTOR, BRIL
CHIMERA)		6wrh PEPTIDASE C16
(SARS-CoV-2)		5 / 12
LEU A 185
THR A 210
ALA A 246
VAL A 242
TYR A 213
1.73A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DRX_A_H8GA1201_0
(5HT2B RECEPTOR, BRIL
CHIMERA)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
LEU E  93
VAL E  35
ALA E  27
PHE E   6
ASN E   4
1.46A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DRX_A_H8GA1201_0
(5HT2B RECEPTOR, BRIL
CHIMERA)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
LEU E  93
VAL E  35
ALA E  27
ASN E   4
VAL E 151
1.53A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DRX_A_H8GA1201_0
(5HT2B RECEPTOR, BRIL
CHIMERA)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
LEU A  93
VAL A  35
ALA A  27
ASN A   4
VAL A 151
1.60A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DRX_A_H8GA1201_0
(5HT2B RECEPTOR, BRIL
CHIMERA)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
LEU A  93
VAL A  35
ALA A  27
PHE A   6
ASN A   4
1.46A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DRX_A_H8GA1201_0
(5HT2B RECEPTOR, BRIL
CHIMERA)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
LEU D  93
VAL D  35
ALA D  27
PHE D   6
ASN D   4
1.50A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DRX_A_H8GA1201_0
(5HT2B RECEPTOR, BRIL
CHIMERA)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
LEU C  93
VAL C  35
ALA C  27
PHE C   6
ASN C   4
1.53A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DRX_A_H8GA1201_0
(5HT2B RECEPTOR, BRIL
CHIMERA)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
LEU B  93
VAL B  35
ALA B  27
PHE B   6
ASN B   4
1.48A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DRX_A_H8GA1201_0
(5HT2B RECEPTOR, BRIL
CHIMERA)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
LEU B  93
VAL B  35
ALA B  27
ASN B   4
VAL B 151
1.61A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DRX_A_H8GA1201_0
(5HT2B RECEPTOR, BRIL
CHIMERA)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
LEU B  93
VAL B  35
ALA B  27
ASN B   4
VAL B 151
1.61A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DRX_A_H8GA1201_0
(5HT2B RECEPTOR, BRIL
CHIMERA)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
LEU A  93
VAL A  35
ALA A  27
PHE A   6
ASN A   4
1.50A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DRX_A_H8GA1201_0
(5HT2B RECEPTOR, BRIL
CHIMERA)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
LEU E  93
VAL E  35
ALA E  27
PHE E   6
ASN E   4
1.47A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DRX_A_H8GA1201_0
(5HT2B RECEPTOR, BRIL
CHIMERA)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
LEU D  93
VAL D  35
ALA D  27
PHE D   6
ASN D   4
1.55A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DRX_A_H8GA1201_0
(5HT2B RECEPTOR, BRIL
CHIMERA)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
LEU B  93
VAL B  35
ALA B  27
PHE B   6
ASN B   4
1.49A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DRX_A_H8GA1201_0
(5HT2B RECEPTOR, BRIL
CHIMERA)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
LEU E  93
VAL E  35
ALA E  27
ASN E   4
VAL E 151
1.57A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DRX_A_H8GA1201_0
(5HT2B RECEPTOR, BRIL
CHIMERA)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
LEU C  93
VAL C  35
ALA C  27
PHE C   6
ASN C   4
1.50A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DRX_A_H8GA1201_0
(5HT2B RECEPTOR, BRIL
CHIMERA)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
LEU A  93
VAL A  35
ALA A  27
ASN A   4
VAL A 151
1.60A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DRX_A_H8GA1201_0
(5HT2B RECEPTOR, BRIL
CHIMERA)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
LEU C  93
VAL C  35
ALA C  27
PHE C   6
ASN C   4
1.52A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DRX_A_H8GA1201_0
(5HT2B RECEPTOR, BRIL
CHIMERA)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
LEU B  93
VAL B  35
ALA B  27
PHE B   6
ASN B   4
1.47A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DRX_A_H8GA1201_0
(5HT2B RECEPTOR, BRIL
CHIMERA)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
LEU A  93
VAL A  35
ALA A  27
PHE A   6
ASN A   4
1.50A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DRX_A_H8GA1201_0
(5HT2B RECEPTOR, BRIL
CHIMERA)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
LEU B  93
VAL B  35
ALA B  27
ASN B   4
VAL B 151
1.58A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DRX_A_H8GA1201_0
(5HT2B RECEPTOR, BRIL
CHIMERA)		7btf NSP12
NSP8
(SARS-CoV-2)		5 / 12
LEU B 184
SER B 164
PHE A 407
ASN A 447
VAL A 405
1.74A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DRX_A_H8GA1201_0
(5HT2B RECEPTOR, BRIL
CHIMERA)		7btf NSP12
(SARS-CoV-2)		5 / 12
LEU A 630
THR A 687
ALA A 688
PHE A 480
VAL A 637
1.67A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DRX_A_H8GA1201_0
(5HT2B RECEPTOR, BRIL
CHIMERA)		7bv2 NSP12
(SARS-CoV-2)		5 / 12
LEU A 731
VAL A 704
PHE A 745
ALA A 777
TYR A 788
1.63A
None